SCHEMBL15939770

SCHEMBL15939770

COC(=O)c1scc(-c2ccc(OC)cc2)c1N

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 5/20 0.53
CYP1A2 P05177 1/20 0.53
CYP2D6 P10635 1/20 0.53
CYP2C9 P11712 1/20 0.53
CYP2C19 P33261 1/20 0.53
ALDH1A1 P00352 5/20 0.52
MAPT P10636 5/20 0.52
HSD17B10 Q99714 3/20 0.52
HPGD P15428 3/20 0.52
LMNA P02545 2/20 0.52
GAA P10253 1/20 0.52
RECQL P46063 1/20 0.52
MAPK1 P28482 2/20 0.51
TSHR P16473 1/20 0.51
OPRD1 P41143 1/20 0.51
PRKCZ Q05513 2/20 0.50
PKM P14618 1/20 0.49
KMT2A Q03164 2/20 0.49
MEN1 O00255 1/20 0.49
CA1 P00915 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15940088 0.88 MAPT (0.67) KDM4EALDH1A1MAPTHSD17B10HPGD
SCHEMBL14975744 0.86 PRKCZ (0.68) KDM4EALDH1A1MAPTHSD17B10HPGD
SCHEMBL15940251 0.86 IKBKB (0.56) KDM4EALDH1A1MAPTHSD17B10HPGD
SCHEMBL15940253 0.86 KDM4E (0.56) KDM4EALDH1A1MAPTHSD17B10HPGD
SCHEMBL1883906 0.86 ALDH1A1 (0.66) KDM4EALDH1A1MAPTHSD17B10HPGD
SCHEMBL24128292 0.84 ALDH1A1 (0.51) KDM4EALDH1A1MAPTHSD17B10HPGD
SCHEMBL15940127 0.84 ALDH1A1 (0.74) KDM4EALDH1A1MAPTHSD17B10HPGD
SCHEMBL15940360 0.82 ALDH1A1 (0.70) KDM4EALDH1A1MAPTHSD17B10HPGD
SCHEMBL3995640 0.82 ALDH1A1 (0.76) KDM4ECYP1A2CYP2D6CYP2C9CYP2C19
SCHEMBL15940164 0.81 SLC6A3 (0.58) KDM4ECYP1A2CYP2C9CYP2C19ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9260448-B2 Thienopyrimidinone derivatives as mGluR1 antagonists KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) 2016-02-16 US disclosed
US-20140228565-A1 THIENOPYRIMIDINONE DERIVATIVES AS mGluR1 ANTAGONISTS KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) 2014-08-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140228565-A1 THIENOPYRIMIDINONE DERIVATIVES AS mGluR1 ANTAGONISTS GRM1, GRIN1, GRM2 KDM4E 4008/4885CYP1A2 3437/4885CYP2D6 1789/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.